Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy

Highlights • We report analysis of the polymorphism of IL28B (rs8099917 and rs12979860) and association of these in terms of virological response to PEG-INF plus ribavirin treatment. • We found three types of genotypes in rs8099917 of IL28B i.e. 60.0% patients with wild type TT, 36.2% with heterozyg...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2015-01, Vol.30 (C), p.91-97
Main Authors: Aziz, Hafsa, Raza, Abida, Ali, Khawar, Khattak, Jabar Zaman Khan, Irfan, Javaid, Gill, Muzaffar Lateef
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Female
Genotype
HCV genotype 3
Hepacivirus - genetics
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - genetics
Hepatitis C, Chronic - virology
Humans
IL28B
Infectious Disease
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Male
Pakistan
PEG-IFN
Polyethylene Glycols - therapeutic use
Polymorphism, Single Nucleotide
Pulmonary/Respiratory
Ribavirin - therapeutic use
Treatment Outcome
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We report analysis of the polymorphism of IL28B (rs8099917 and rs12979860) and association of these in terms of virological response to PEG-INF plus ribavirin treatment. • We found three types of genotypes in rs8099917 of IL28B i.e. 60.0% patients with wild type TT, 36.2% with heterozygous TG minor type and 3.8% with GG. The frequency of CC genotype of rs12979860 is 54.3%, CT 37.1% and TT 8.6% genotypes (rs12979860). Overall SVR was achieved in 68.6% of patients. Higher SVR was achieved for patients having favorable genotype CC with 84.2% as compared to 56.4% and 22% for minor genotype CT and TT respectively(p = 0.0001). Moreover we did not find significant association of SVR to antiviral treatment in patients with TT genotypes (71.9% p = 0.36). In addition the rate of RVR was significantly higher in patients with major genotype TT (88.9%, p = 0.04). • These findings helps in the prediction of response that lead to open new way of management of therapy in terms of shorter treatment that ultimately reduce the cost and side effect of therapy.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2014.09.021